Business, energy, technology, markets and global industry news from Business News Today

Skip to content

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

Home
Pharma & Biotech
Medical Devices & Diagnostics
Features & Analysis

South Australian immunoGENomics Cancer Institute

PharmaDeviceNews South Australian immunoGENomics Cancer Institute

Pharma & Biotech

AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study

by Pallavi Madhiraju
October 24, 2026
0 Comments

AdvanCell reports an 80% PSA response and 11.2-month median rPFS with ADVC001. Small Phase 1 numbers leave important efficacy questions.

Read More

Latest news and features

What does GondolaBio’s Children’s Tumor Foundation partnership mean for NF1 drug research?
Summit Therapeutics partners with Lunit to study AI tumor biomarkers for ivonescimab
Travere Therapeutics FILSPARI shows sustained biomarker reductions in Phase 3 PROTECT study
Genialis AI predicts cancer treatment response in small clinical trials using biology-first models
AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
Galderma wins China approval for Relfydess, but can its six-month wrinkle treatment challenge established Botox rivals?
EQT offers QIAGEN shareholders a 40% premium, but can its €10.8bn diagnostics bet unlock faster growth?
Merck and Moderna report 42% lower melanoma recurrence risk in Phase 3 mRNA trial
Drug Farm reports DF-003 reduces kidney fibrosis in preclinical ALPK1 study
Gilead Sciences makes a $1.275bn bet on an early-stage oral drug. Can HCXT-2001 challenge injectable IBD therapies?
Innate Pharma faces a crucial November update. Can its ADC pipeline and Sobi deal strengthen its position?
Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform

POPULAR NEWS

Representative image of a clinician reviewing skeletal imaging, illustrating Mirum Pharmaceuticals and Incyte’s zilurgisertib Phase 2 progress in fibrodysplasia ossificans progressiva and the rare disease treatment questions facing regulators.

Pharma & Biotech

Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment

June 15, 2026

Viridian Therapeutics’ FDA-approved Lumvoa enters the thyroid eye disease market with a five-infusion treatment course, intensifying competition with Tepezza. Representative image.

Medical Devices & Diagnostics

FDA approves Genentech’s ENSPRYNG as first at-home treatment for thyroid eye disease

October 18, 2026

Niagen Bioscience’s NB4168 has secured U.S. FDA Rare Pediatric Disease and European orphan designations as the company advances the experimental ataxia telangiectasia therapy toward human trials. Representative image.

Pharma & Biotech

Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?

July 14, 2026

Latest business and industry news

Meta (NASDAQ: META) near $646: Can $140bn AI spending justify its $1.65tn valuation?
Netflix profit jumps 37%, yet weaker ads reopen the question of where growth comes from next
Safran aftermarket revenue jumps 18.7% as aircraft shortages strengthen engine economics
Deckers (DECK) near $81: Is 11x earnings cheap when HOKA growth is slowing?
Hermès growth slows to 4.3% as China tests the limits of luxury resilience

TAGS

AstraZeneca clinical trials Eli Lilly and Company European Medicines Agency FDA FDA approval immunotherapy Inc. Johnson & Johnson medical devices non-small cell lung cancer oncology precision oncology U.S. Food and Drug Administration United States Food and Drug Administration

About PharmaDeviceNews
Disclaimer
Editorial Policy
Privacy Policy
Contact Us

© 2026 PharmaDeviceNews.com. All rights reserved.